IMMUNOGENICITY IN PERUVIAN VOLUNTEERS OF A BOOSTER DOSE OF ORAL CHOLERA VACCINE CONSISTING OF WHOLE CELLS PLUS RECOMBINANT-B-SUBUNIT

被引：12

作者：

BEGUE, RE

CASTELLARES, G

CABEZAS, C

SANCHEZ, JL

MEZA, R

WATTS, DM

TAYLOR, DN

机构：

[1] UNIV NACL MAYOR,INST MED TROP DANIEL A CARRION,SAN MARCOS,TX

[2] UNIV PERUANA CAYETANO HEREDIA,LIMA,PERU

[3] INST NACL SALUD,LIMA,PERU

[4] NAVAL MED RES INST DETACHMENT,UNIT 3800,LIMA,PERU

[5] USA,MED RES UNIT 3501,RIO JANEIRO,BRAZIL

来源：

INFECTION AND IMMUNITY | 1995年 / 63卷 / 09期

关键词：

D O I：

10.1128/IAI.63.9.3726-3728.1995

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Forty-nine subjects received two doses of oral cholera vaccine consisting of whole cells plus recombinant B subunit; this was followed by a booster dose one year later. After the primary series, a significant (greater than twofold) increase in the levels of vibriocidal, anti-cholera toxin immunoglobulin G and anti-cholera toxin immunoglobulin A antibodies occurred in 54, 88, and 81% of the subjects, respectively. Within one year, titers decreased to levels close to baseline. A booster dose then induced rises similar to those which occurred after the initial vaccination. The results suggest that 1-year booster doses may be necessary to maintain immunity against cholera in Latin America.

引用

页码：3726 / 3728

页数：3

共 11 条

[1]

BEGUE RE, IN PRESS VACCINE

[2]

CLEMENS JD, 1986, LANCET, V2, P124

[3] B-SUBUNIT-WHOLE CELL AND WHOLE CELL-ONLY ORAL VACCINES AGAINST CHOLERA - STUDIES ON REACTOGENICITY AND IMMUNOGENICITY [J].